PMID: 7025070Aug 1, 1981Paper

Prostaglandins in myocardial: with emphasis on myocardial preservation

Prostaglandins and Medicine
B I Jugdutt

Abstract

Various therapies during early hours of acute myocardial infarction (AMI) have been suggested to protect ischemic myocardium and reduce infarct size. Despite reports that prostaglandins (PGs) are released during myocardial ischemia, and that prostacyclin (PGI2) and thromboxane A2 (TXA2) have opposing effects on vasomotion and platelet aggregation, the physiologic roles of PGs, PGI2 and TXA2 in AMI have not been clearly defined. However, in pharmacologic doses, experimental evidence suggests that vasodilator PGs might be beneficial, and vasoconstrictor PGs might be deleterious, in AMI. Recent recognition that coronary spasm is frequent in AMI has led to the notion that an increased PGI2/TXA2 ratio might be desirable. Thus, exogenous PGE1, exogenous PGI2 or tis more stable analogs, drugs that stimulate PGI2 release, and inhibitors of TXA2 and harmful PGs are potential agents for protective therapy in AMI.

References

May 18, 1978·The New England Journal of Medicine·P Needleman, G Kaley
Jun 1, 1975·The Journal of Clinical Investigation·R W AlexanderT Cooper
Dec 1, 1974·The Journal of Clinical Investigation·R A KlonerR B Jennings
Sep 1, 1974·The Journal of Physiology·S AfonsoG G Rowe
Jul 26, 1972·Nature: New Biology·R FlowerJ R Vane
Jan 1, 1972·The American Journal of Cardiology·S Sherry
Dec 1, 1972·The American Journal of Cardiology·J I HaftR Oestreicher
Mar 1, 1973·The Journal of Clinical Investigation·P LibbyE Braunwald
Sep 1, 1973·Cardiovascular Research·C J Limas, J N Cohn
Jul 1, 1966·Circulation Research·A KrugG Korb
Jan 1, 1980·The American Journal of Cardiology·E MorcillioB Pitt
Jul 1, 1980·Journal of Molecular and Cellular Cardiology·G G AhumadaP Needleman
Feb 1, 1980·Prostaglandins·J O'GradyS Moncada
May 1, 1981·Clinical Cardiology·B I Jugdutt, L C Becker

❮ Previous
Next ❯

Citations

Aug 22, 1986·European Journal of Pharmacology·H E Aksulu, R K Türker
May 1, 1983·Prostaglandins, Leukotrienes, and Medicine·I MoritaS Murota
Oct 1, 1984·Circulation·P J Cannon
Dec 26, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hao YinCynthia Ju
Nov 1, 1982·Drug Intelligence & Clinical Pharmacy·S L Roehl, R J Townsend
Feb 28, 2021·Signal Transduction and Targeted Therapy·Bei WangDao Wen Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.